Triumvira Immunologics
Dr. Renier Brentjens obtained an MD/PhD (microbiology) from the University at Buffalo, completed a residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated the initial preclinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs).
Following the completion of his medical oncology training, Dr. Brentjens became the principal investigator of his own laboratory. As a principal investigator, Dr. Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second-generation CAR modified T cell clinical trials.
Additionally, work in the Brentjens lab has expanded this CAR technology to target additional tumor antigens expressed on other malignancies including solid tumors. In September 2021, Dr. Brentjens joined Roswell Park Comprehensive Cancer Center as Deputy Director, Chair of Medicine, and The Katherine Anne Gioia Endowed Chair in Cancer Medicine, with a goal to advance cell and immune cancer therapies.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Triumvira Immunologics
1 followers
At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you.